Ocular Therapeutix (OCUL) Competitors $5.93 -1.21 (-16.95%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$5.88 -0.05 (-0.93%) As of 03/3/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends OCUL vs. SWTX, OGN, RARE, PTCT, ADMA, RNA, ZLAB, BHVN, ALVO, and RXRXShould you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), ADMA Biologics (ADMA), Avidity Biosciences (RNA), Zai Lab (ZLAB), Biohaven (BHVN), Alvotech (ALVO), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Ocular Therapeutix vs. SpringWorks Therapeutics Organon & Co. Ultragenyx Pharmaceutical PTC Therapeutics ADMA Biologics Avidity Biosciences Zai Lab Biohaven Alvotech Recursion Pharmaceuticals Ocular Therapeutix (NASDAQ:OCUL) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings. Is OCUL or SWTX more profitable? SpringWorks Therapeutics has a net margin of -134.73% compared to Ocular Therapeutix's net margin of -283.74%. Ocular Therapeutix's return on equity of -45.18% beat SpringWorks Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ocular Therapeutix-283.74% -45.18% -30.87% SpringWorks Therapeutics -134.73%-46.74%-41.12% Do analysts recommend OCUL or SWTX? Ocular Therapeutix currently has a consensus price target of $17.00, indicating a potential upside of 186.68%. SpringWorks Therapeutics has a consensus price target of $73.20, indicating a potential upside of 37.39%. Given Ocular Therapeutix's higher probable upside, equities analysts clearly believe Ocular Therapeutix is more favorable than SpringWorks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocular Therapeutix 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83SpringWorks Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor OCUL or SWTX? Ocular Therapeutix received 331 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 71.62% of users gave SpringWorks Therapeutics an outperform vote while only 70.14% of users gave Ocular Therapeutix an outperform vote. CompanyUnderperformOutperformOcular TherapeutixOutperform Votes43770.14% Underperform Votes18629.86% SpringWorks TherapeuticsOutperform Votes10671.62% Underperform Votes4228.38% Do insiders and institutionals hold more shares of OCUL or SWTX? 59.2% of Ocular Therapeutix shares are held by institutional investors. 3.5% of Ocular Therapeutix shares are held by company insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, OCUL or SWTX? Ocular Therapeutix has higher earnings, but lower revenue than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcular Therapeutix$61.44M15.17-$80.74M-$1.32-4.49SpringWorks Therapeutics$191.59M20.84-$325.10M-$3.48-15.31 Does the media prefer OCUL or SWTX? In the previous week, SpringWorks Therapeutics had 5 more articles in the media than Ocular Therapeutix. MarketBeat recorded 19 mentions for SpringWorks Therapeutics and 14 mentions for Ocular Therapeutix. SpringWorks Therapeutics' average media sentiment score of 0.51 beat Ocular Therapeutix's score of 0.46 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral SpringWorks Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, OCUL or SWTX? Ocular Therapeutix has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. SummaryOcular Therapeutix beats SpringWorks Therapeutics on 9 of the 17 factors compared between the two stocks. Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCUL vs. The Competition Export to ExcelMetricOcular TherapeutixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$932.30M$7.20B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-4.496.1524.9519.21Price / Sales15.17187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book7.516.447.334.28Net Income-$80.74M$139.03M$3.18B$247.04M7 Day Performance-11.89%-5.52%-4.42%-4.36%1 Month Performance-21.46%-8.56%-6.07%-5.60%1 Year Performance-44.84%-14.59%11.42%3.38% Ocular Therapeutix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCULOcular Therapeutix3.042 of 5 stars$5.93-16.9%$17.00+186.7%-44.8%$1.12B$61.44M-4.49230Earnings ReportOptions VolumeNews CoverageGap DownHigh Trading VolumeSWTXSpringWorks Therapeutics2.6348 of 5 stars$56.56-2.9%$71.50+26.4%+4.5%$4.21B$191.59M-16.25230Short Interest ↓OGNOrganon & Co.4.8597 of 5 stars$15.08-0.9%$20.80+38.0%-18.3%$3.88B$6.40B4.5310,000RAREUltragenyx Pharmaceutical4.5398 of 5 stars$41.84-1.8%$93.50+123.5%-23.2%$3.87B$560.23M-6.601,276Insider TradePTCTPTC Therapeutics3.7228 of 5 stars$50.02-1.3%$58.85+17.6%+65.5%$3.86B$900.66M-8.421,410Analyst RevisionADMAADMA Biologics3.0855 of 5 stars$15.52-2.0%$21.25+36.9%+186.8%$3.67B$382.81M55.43530Positive NewsRNAAvidity Biosciences1.121 of 5 stars$30.53-1.9%$65.80+115.5%+45.3%$3.64B$10.12M-10.60190Earnings ReportAnalyst RevisionGap DownZLABZai Lab2.4705 of 5 stars$32.95-2.5%$55.00+66.9%+50.4%$3.61B$355.75M-11.902,175Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeBHVNBiohaven3.4763 of 5 stars$35.46-3.9%$63.15+78.1%-35.5%$3.59BN/A-3.79239Earnings ReportUpcoming EarningsNews CoveragePositive NewsALVOAlvotech2.2676 of 5 stars$11.87-3.3%$18.00+51.6%-29.6%$3.58B$93.38M-6.421,026RXRXRecursion Pharmaceuticals2.2965 of 5 stars$9.00-3.0%$8.75-2.8%-48.6%$3.52B$44.58M-5.88400Earnings ReportGap Up Related Companies and Tools Related Companies SWTX Competitors OGN Competitors RARE Competitors PTCT Competitors ADMA Competitors RNA Competitors ZLAB Competitors BHVN Competitors ALVO Competitors RXRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCUL) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
